BioSpace News Archive

SCYNEXIS, Inc. (NASDAQ: SCYX), today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) of an additional indication for BREXAFEMME® (ibrexafungerp tablets) for the prevention of recurrent vulvovaginal candidiasis (RVVC).

Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma.

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it received written notice from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) stating that the Company has regained compliance with the Nasdaq minimum bid price.

Albireo Pharma, Inc. today announced the presentation of seven abstracts/posters at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022, being held June 22 – 26 in London.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that Dr. Helen Torley , president and chief executive officer, is scheduled to present and host investor meetings at the Goldman Sachs 43rd Annual Global Healthcare Conference being held in Rancho Palos Verdes, CA on June 14-16, 2022 .

Nephron Research LLC (“Nephron Research”), the market’s leading independent research provider for healthcare, is pleased to announce its expansion into the Medical Devices & Supplies sector with the addition of Chris Pasquale, who has joined the firm as a partner.

CNS Pharmaceuticals, Inc. today announced that Sigmund Hsu , MD, member of the Company’s Scientific Advisory Board, presented an overview of its ongoing clinical trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.

InVivo Therapeutics Announces Publication of 12- and 24-month Data for INSPIRE 1.0 Study in Peer-Reviewed Neurosurgery.

Xilis expands CAB to five members to help company develop its MicroOrganoSphere™ technology.

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today issued the following letter to its shareholders in response to the concerns expressed by Iroquois Capital Management (Iroquois) in its letter to the PharmaCyte Board of Directors.